Siu Adrian, Steffens Daniel, Ansari Nabila, Karunaratne Sascha, Solanki Henna, Ahmadi Nima, Solomon Michael, Moran Brendan, Koh Cherry
Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, C/O Royal Prince Alfred Hospital, Missenden Road, PO Box M 157, Camperdown, NSW, 2050, Australia.
Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia.
Tech Coloproctol. 2024 Feb 20;28(1):35. doi: 10.1007/s10151-024-02911-9.
Rural Australians typically encounter disparities in healthcare access leading to adverse health outcomes, delayed diagnosis and reduced quality of life (QoL) parameters. These disparities may be exacerbated in advanced malignancies, where treatment is only available at highly specialised centres with appropriate multidisciplinary expertise. Thus, this study aims to determine the association between patient residence on oncological, surgical and QoL outcomes following cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC).
A retrospective analysis was conducted on consecutive patients undergoing CRS and HIPEC at Royal Prince Alfred Hospital from January 2017 to March 2022. On the basis of their postcode of residence, patients were stratified into metropolitan and regional groups. Data encompassing demographics, oncological, surgical and QoL outcomes were compared. Statistical analysis included chi-square test, t-tests and Kaplan-Meier survival curves.
Among the 317 patients, 228 (72%) were categorised as metropolitan and 89 (28%) as regional. Metropolitan patients presented higher rates of recurrence (61.8% versus 40.0%, p = 0.014) and shorter overall mean survival [3.8 years (95% CI: 3.44-4.09) versus 4.2 years (95% CI: 3.76-4.63), p = 0.019] compared with regional patients. No other statistically significant differences were observed in oncological, surgical and QoL outcomes.
Most oncological, surgical and QoL parameters did not differ by geographical location of patients undergoing CRS and HIPEC for peritoneal malignancies at a high-volume quaternary referral centre. Observed differences in recurrence and survival may be attributed to the selective nature of surgical referrals and variable follow-up patterns. Future research should focus on characterising referral pathways and its influence on post-operative outcomes.
澳大利亚农村地区居民在医疗保健可及性方面通常存在差异,这导致了不良健康后果、诊断延迟和生活质量(QoL)参数降低。在晚期恶性肿瘤中,这些差异可能会加剧,因为治疗仅在拥有适当多学科专业知识的高度专业化中心提供。因此,本研究旨在确定接受细胞减灭术(CRS)和热灌注化疗(HIPEC)后患者居住地与肿瘤学、手术和生活质量结果之间的关联。
对2017年1月至2022年3月在皇家阿尔弗雷德王子医院接受CRS和HIPEC的连续患者进行回顾性分析。根据患者居住邮政编码,将患者分为大都市组和地区组。比较了包括人口统计学、肿瘤学、手术和生活质量结果的数据。统计分析包括卡方检验、t检验和Kaplan-Meier生存曲线。
在317例患者中,228例(72%)被归类为大都市组,89例(28%)为地区组。与地区组患者相比,大都市组患者的复发率更高(61.8%对40.0%,p = 0.014),总体平均生存期更短[3.8年(95%CI:3.44 - 4.09)对4.2年(95%CI:3.76 - 4.63),p = 0.019]。在肿瘤学、手术和生活质量结果方面未观察到其他统计学上的显著差异。
在一家大型四级转诊中心,接受CRS和HIPEC治疗腹膜恶性肿瘤的患者,其大多数肿瘤学、手术和生活质量参数在地理位置上没有差异。观察到的复发和生存差异可能归因于手术转诊的选择性性质和不同的随访模式。未来的研究应侧重于描述转诊途径及其对术后结果的影响。